{"id":5382,"date":"2026-09-17T09:53:24","date_gmt":"2026-09-17T07:53:24","guid":{"rendered":"https:\/\/docuply.io\/?page_id=5382"},"modified":"2026-09-17T10:02:15","modified_gmt":"2026-09-17T08:02:15","slug":"21-cfr-part-11-electronic-signatures-guide","status":"publish","type":"page","link":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/","title":{"rendered":"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"21\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Last updated: 17 September 2026<\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tFor electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and complete audit trail, controlled access with unique user authentication, and an inseparable link between signature and record. Every signature must carry the signer’s printed name, the date and time, and the meaning (review, approval, authorship). “Part 11 compliant” is not a property any software owns on its own: no vendor can sell you compliance. The vendor supplies the technical controls and validation documentation; the sponsor remains accountable for the validated system as operated. This guide explains the requirements in practical terms for QA leads, then compares how leading eQMS vendors implement Part 11 signatures.

What is 21 CFR Part 11?<\/h2>
21 CFR Part 11 is the US FDA regulation setting out the criteria under which electronic records and electronic signatures are considered trustworthy, reliable and generally equivalent to paper records bearing handwritten signatures. The full regulatory text is available in the eCFR<\/a>; the rule was published on 20 March 1997 and took effect on 20 August 1997.

Scope matters. Part 11 applies only to records that a predicate rule (such as GMP, GCP or GLP) already requires and that a company chooses to keep electronically rather than on paper. In its 2003 “Scope and Application” guidance<\/a>, the FDA said it would interpret Part 11 narrowly and exercise enforcement discretion over validation, audit trails, record retention and record copying. The underlying predicate rules, by contrast, are enforced in full.

In Europe, EU GMP Annex 11<\/a> fills a comparable role. Annex 11 is broader, covering the whole lifecycle of computerised systems. On 7 July 2025 the European Commission, together with PIC\/S, published a substantial draft revision that expands Annex 11 from five to 19 pages (17 chapters plus a glossary) and introduces, among other things, multi-factor authentication and eIDAS alignment for electronic signatures; the consultation closed on 7 October 2025.

What does 21 CFR Part 11 require of electronic signatures?<\/h2>
The requirements sit across Subpart B (Electronic Records) and Subpart C (Electronic Signatures). For QA leads they translate into eight building blocks.

1. System validation (11.10a).<\/b> The system must be validated to demonstrate accuracy, reliability and the ability to discern invalid or altered records. Without validation, no signature holds up.

2. Audit trail (11.10e).<\/b> Secure, computer-generated, time-stamped audit trails must independently record who created, changed or deleted which record and when. Earlier entries must not be obscured.

3. Access control and authentication (11.10d, 11.10g, 11.300).<\/b> System access stays limited to authorised individuals. Non-biometric signatures need at least two components under 11.200<\/a>, typically a user ID plus password, with password controls such as uniqueness and periodic ageing.

4. Signature manifestation (11.50).<\/b> Every signed record must visibly show the signer’s printed name, the date and time, and the meaning of the signature, and must do so in any human-readable output such as a printout or screen display.

5. Signature\/record linking (11.70).<\/b> Signatures must be linked to their records so they cannot be excised, copied or transferred by ordinary means.

6. Meaning of the signature.<\/b> Part 11 requires each signature to carry a clear meaning: authorship, review or approval. The same person may sign in different roles; the system must capture which one.

7. Training and accountability (11.10i, 11.10j).<\/b> Those who develop, maintain or use the systems must be demonstrably trained. Written policies must hold individuals accountable for actions taken under their signatures.

8. Certification to the FDA (11.100c).<\/b> Before first use, an organisation must certify to the FDA in writing that its electronic signatures are the legally binding equivalent of handwritten signatures. This letter (a Letter of Non-Repudiation Agreement) is submitted with a traditional handwritten signature.

Part 11 also distinguishes closed from open systems. In a closed system<\/i>, those responsible for the records control access, so the controls in 11.10 suffice. In an open system<\/i> (11.30) they do not, which is why additional measures such as encryption and digital signature standards are required.

What is the difference between an e-signature and a digital signature?<\/h2>
The terms are often confused but mean different things. An electronic signature<\/i> is a legal concept: under Part 11 (11.3)<\/a>, a compilation of symbols a person executes as the legally binding equivalent of their signature. A digital signature<\/i> is a cryptographic method that, under Part 11, is based on cryptographic techniques of originator authentication so that the signer’s identity and the data’s integrity can be verified (in short, PKI).

For closed systems, Part 11 does not require a digital signature; a combined ID-code-plus-password approach is sufficient. Only for open systems, where those responsible for the records do not control system access, does the regulation call for additional measures such as encryption and appropriate digital signature standards.

In the EU, the eIDAS Regulation (EU) 910\/2014<\/a> defines three tiers: simple (SES), advanced (AES) and qualified electronic signature (QES). Only the QES is legally equivalent to a handwritten signature. Note that eIDAS and Part 11 serve different purposes. A QES is neither required for Part 11 nor automatically sufficient, because Part 11 additionally demands system validation, an audit trail and signature meaning.

What does “Part 11 compliant” mean for a hosted eQMS?<\/h2>
The key sentence first: no vendor can sell you Part 11 compliance. Compliance is not a property of the software but of the validated whole made up of software, procedures and people. This follows from the shared-responsibility principle.

The vendor supplies the technical controls (audit trail, signature components, access control, time stamps), vendor documentation of how the system works and, with modern cloud vendors, a pre-validated package of pre-executed IQ\/OQ documents. That materially reduces the effort.

The customer retains the intended-use assessment (which of your records are in Part 11 scope?), your own SOPs, staff training, day-to-day access administration, the Performance Qualification (PQ) in your process and change control on updates. A vendor can hand you the validation documents, but it cannot decide for you what you use the system for.

On effort in numbers: a complete year-one CSV engagement typically costs a mid-size life-science company between 50,000 and 150,000 US dollars once all cost components are counted; the Installation Qualification alone can run 7,000 to 20,000 US dollars at external consultant rates of 175 to 250 US dollars per hour. Manual validation of a complex GAMP Category 4 system often takes eight to 18 weeks. A pre-validated system shortens this phase considerably, because protocol authoring and much of the test execution fall away. The FDA reinforced this risk-based approach in its final Computer Software Assurance (CSA) guidance<\/a> (September 2025, updated February 2026).

On hosting region: location alone is not decisive. Under the US CLOUD Act (2018), US authorities can compel data from US providers even when it sits in Frankfurt or Dublin, which is in tension with Article 48 GDPR and the Schrems II ruling (2020). For sensitive data, a vendor with no US corporate ties or with EU-managed encryption has the edge. For a fuller side-by-side, see our eQMS software comparison<\/a>.

Vendor comparison: how do eQMS vendors implement Part 11 signatures?<\/h2>
Every eQMS below supports, per the vendor, Part 11 and Annex 11 signatures with an audit trail and access control. The differences lie in the validation model, the hosting region and the target company size. Docuply, publisher of this page, is held to the same standard as every other vendor.
\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
Vendor<\/th>\r\nPart 11 implementation<\/th>\r\nPre-validation<\/th>\r\nHosting region<\/th>\r\nTarget size<\/th>\r\n<\/tr>\r\n<\/thead>\r\n
Docuply<\/strong><\/td>\r\nPart 11 + Annex 11, audit trail with chained entries (per vendor)<\/td>\r\nContinuously pre-validated: IQ\/OQ included, plus PQ\/UAT template<\/td>\r\nEU (Germany), ISO 27001<\/td>\r\nBiotech: from Phase I to marketing authorisation and CROs (up to approx. 150 staff)<\/td>\r\n<\/tr>\r\n
MasterControl<\/strong><\/td>\r\nPart 11 + Annex 11, signature-record linking<\/td>\r\nValidation toolkit and services (per vendor, reduced effort)<\/td>\r\nUS company, AWS incl. EU (Germany)<\/td>\r\nSMB to enterprise<\/td>\r\n<\/tr>\r\n
Veeva Vault QMS<\/strong><\/td>\r\nPart 11 + Annex 11, comprehensive<\/td>\r\nValidation package per release (IQ\/OQ, per vendor)<\/td>\r\nUS company, EU data centres (Germany\/UK\/Ireland) on AWS<\/td>\r\nMid-market to enterprise (Basics\/QuickVault for small)<\/td>\r\n<\/tr>\r\n
Qualio<\/strong><\/td>\r\nPart 11 + Annex 11<\/td>\r\nPre-validated (per vendor, only 1% of customers validate themselves)<\/td>\r\nUS (cloud)<\/td>\r\nStartups\/scale-ups<\/td>\r\n<\/tr>\r\n
SimplerQMS<\/strong><\/td>\r\nPart 11 + Annex 11<\/td>\r\nFully validated with continuous re-validation<\/td>\r\nAWS, EU region selectable<\/td>\r\nLife-science SMEs<\/td>\r\n<\/tr>\r\n
Dot Compliance<\/strong><\/td>\r\nPart 11 + Annex 11, MFA and signature meaning<\/td>\r\nFull validation package included<\/td>\r\nSalesforce-native; EU residency not confirmed by vendor<\/td>\r\nStartups to enterprise<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<\/div>
Docuply.<\/b> A young German vendor from Mannheim, focused on clinical biotechs from Phase I to approval and companies up to roughly 150 staff. Strengths: EU hosting in Germany, ISO 27001, IQ\/OQ documentation at no surcharge, set-up in minutes, a transparent list price of 99 euros per user per month. Limits, stated honestly: a clinical rather than MedTech focus, a deliberately lean and less configurable interface, a shorter track record than established players, and API integrations still on the roadmap.

MasterControl.<\/b> An established vendor for GMP\/QSR manufacturers. Strengths: robust document, training, CAPA and audit management, plus a validation toolkit. Hosted on AWS with an EU location in Germany. Limits: the interface and reporting are seen as complex, and pricing is high (from 25,000 US dollars per year for the Basic plan per Capterra).

Veeva Vault QMS.<\/b> The market leader for life-science content, deeply integrated with eTMF, RIM and Safety. Every release ships, per the vendor, in a validated environment with IQ\/OQ, and EU data centres in Germany, the UK and Ireland are available. Limits: high cost (no list prices) and lengthy full implementations; smaller firms are served by the Veeva Basics and QuickVault programmes.

Qualio.<\/b> A cloud-native eQMS for startups and scale-ups, very easy to use, with a pre-validated package and go-live often within 30 to 60 days. Limits: users report limited depth in some modules and one-document-at-a-time change control.

SimplerQMS.<\/b> A pre-validated, Microsoft 365-integrated eQMS on AWS with a selectable EU region. All-inclusive pricing (per the vendor, from 17,500 US dollars per year for up to 15 users). Limits: the interface is perceived as a Microsoft add-on.

Dot Compliance.<\/b> A Salesforce-native, pre-configured eQMS with a full validation package. EU data residency is technically possible via Salesforce Hyperforce but is not explicitly confirmed by the vendor. Limits: a Salesforce learning curve and higher cost owing to the Salesforce foundation.

Why are DocuSign and the like not enough on their own?<\/h2>
Pure e-signature tools do one job well but do not replace a GxP quality system. DocuSign offers separately licensed Life Sciences Modules for Part 11 with authentication, reason for signature and signature manifestation; the standard module is expressly for non-GxP signatures only. Adobe Acrobat Sign provides “Bio-Pharma” settings and a Part 11\/Annex 11 handbook, but stresses that validation responsibility lies with the using organisation, not the provider. Skribble covers SES, AES and QES under eIDAS and Swiss ZertES, aimed mainly at legally binding signatures, hosted in Switzerland.

The catch: these tools provide no version control, no CAPA, and no training, deviation or change-control management. Downloading documents from your validated eQMS, signing them externally and re-uploading them creates copies outside the validated system and breaks the digital chain of custody. They make sense for contracts and external signatures; they do not form the backbone of a GxP quality system.

FAQ<\/h2>
Is a PDF signature Part 11 compliant?<\/b> Not automatically. A PDF signature can be part of a Part 11 compliant solution if the generating system is validated, keeps an audit trail, links the signature inseparably to the record and shows name, date, time and meaning. An isolated PDF signature without those controls is not enough.

Do I have to validate my eQMS myself?<\/b> Accountability for the validated system stays with the sponsor. A pre-validated vendor supplies IQ\/OQ documents and performs software-side testing, but the intended-use assessment and the Performance Qualification in your own process remain yours.

Does 21 CFR Part 11 apply to EU companies?<\/b> Yes, as soon as an EU company keeps electronic records or signatures for activities that fall under FDA predicate rules, for example a planned FDA submission. For the EU market, Annex 11 applies in addition.

Does Part 11 require a digital signature?<\/b> No, not for closed systems, where a two-component signature such as ID code and password suffices. Digital signatures and encryption are named mainly for open systems.

Is an eIDAS qualified electronic signature (QES) automatically Part 11 compliant?<\/b> No. A QES addresses legal equivalence to a handwritten signature but does not cover system validation, the audit trail and signature meaning that Part 11 additionally requires.

Do I need to notify the FDA that I use electronic signatures?<\/b> Yes. Under 11.100(c), before first use an organisation must certify to the FDA in writing that its electronic signatures are the legally binding equivalent of handwritten signatures.

What does the CSA guidance change about Part 11?<\/b> The Computer Software Assurance guidance (final September 2025, updated February 2026) does not change the rule itself but how you validate: risk-based, with less documentation for low-risk functions and recognition of native digital records as evidence.

Is EU hosting enough for GDPR compliance?<\/b> Not on its own. Location is one element; the vendor’s corporate ties (CLOUD Act) and contractual safeguards also matter. A purely EU-based vendor reduces the potential for conflict.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Jan\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Author: <\/strong>Jan Krikava \u2013 Former life sciences consultant who founded Docuply based on his own consulting experience. 14 years\u2019 experience in quality management. B.Sc. in Business Informatics. LinkedIn: linkedin.com\/in\/jan-krikava<\/a><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Docuply: The AI-native eQMS with a fully integrated eTMF for clinical biotech start-ups, pre-validated and ready for immediate use.<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tBook your demo<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Last updated: 17 September 2026 For electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and complete audit trail, controlled access with unique user authentication, and an inseparable link between signature … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":5376,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5382","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\n21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026 | Docuply<\/title>\n<meta name=\"description\" content=\"For electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and (...)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026 | Docuply\" \/>\n<meta property=\"og:description\" content=\"For electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and (...)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/\" \/>\n<meta property=\"og:site_name\" content=\"Docuply\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-17T08:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/docuply.io\/wp-content\/uploads\/2026\/09\/Design-ohne-Titel-1-300x300.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/docuply.io\/wp-content\/uploads\/2026\/07\/eQMS-Comparison-2026-Electronic-Quality-Management-Systems-Biotech-Pharma-2048px-1024x1024.png\" \/>\n<meta name=\"twitter:site\" content=\"@docuplyio\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/\"},\"author\":{\"name\":\"klqcsupport\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#\\\/schema\\\/person\\\/9315e3dd42d30aa7de7672e3f78833f2\"},\"headline\":\"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026\",\"datePublished\":\"2026-09-17T07:53:24+00:00\",\"dateModified\":\"2026-09-17T08:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/\"},\"wordCount\":2154,\"publisher\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/docuply.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Design-ohne-Titel-1.png\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/\",\"url\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/\",\"name\":\"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026 | Docuply\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/docuply.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Design-ohne-Titel-1.png\",\"datePublished\":\"2026-09-17T07:53:24+00:00\",\"dateModified\":\"2026-09-17T08:02:15+00:00\",\"description\":\"For electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and (...)\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/docuply.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Design-ohne-Titel-1.png\",\"contentUrl\":\"https:\\\/\\\/docuply.io\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Design-ohne-Titel-1.png\",\"width\":2048,\"height\":2048,\"caption\":\"21 CFR Part 11 Electronic Signatures: Compliance-Guide und Anbietervergleich 2026\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/21-cfr-part-11-electronic-signatures-guide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/docuply.io\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/docuply.io\\\/en\\\/\",\"name\":\"Docuply\",\"description\":\"Das elektronische Qualit\u00e4ts\u00admanagement\u00adsystem f\u00fcr Pharma-\u00adKMU und Biotech Start-Ups\",\"publisher\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/docuply.io\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#organization\",\"name\":\"Docuply\",\"url\":\"https:\\\/\\\/docuply.io\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/docuply.io\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Docuply-Logo-1.0.svg\",\"contentUrl\":\"https:\\\/\\\/docuply.io\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Docuply-Logo-1.0.svg\",\"width\":2913,\"height\":719,\"caption\":\"Docuply\"},\"image\":{\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/docuplyio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/docuply\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/docuply.io\\\/en\\\/#\\\/schema\\\/person\\\/9315e3dd42d30aa7de7672e3f78833f2\",\"name\":\"klqcsupport\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/da59724f7f91c371ac3ce77a87b08724f7f2ad3567196cf301565601f8e54536?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/da59724f7f91c371ac3ce77a87b08724f7f2ad3567196cf301565601f8e54536?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/da59724f7f91c371ac3ce77a87b08724f7f2ad3567196cf301565601f8e54536?s=96&d=mm&r=g\",\"caption\":\"klqcsupport\"},\"sameAs\":[\"https:\\\/\\\/docuply.io\"],\"url\":\"https:\\\/\\\/docuply.io\\\/en\\\/author\\\/hostingklqc-de\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026 | Docuply","description":"For electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and (...)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/","og_locale":"en_US","og_type":"article","og_title":"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026 | Docuply","og_description":"For electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and (...)","og_url":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/","og_site_name":"Docuply","article_modified_time":"2026-09-17T08:02:15+00:00","og_image":[{"url":"https:\/\/docuply.io\/wp-content\/uploads\/2026\/09\/Design-ohne-Titel-1-300x300.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_image":"https:\/\/docuply.io\/wp-content\/uploads\/2026\/07\/eQMS-Comparison-2026-Electronic-Quality-Management-Systems-Biotech-Pharma-2048px-1024x1024.png","twitter_site":"@docuplyio","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/#article","isPartOf":{"@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/"},"author":{"name":"klqcsupport","@id":"https:\/\/docuply.io\/en\/#\/schema\/person\/9315e3dd42d30aa7de7672e3f78833f2"},"headline":"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026","datePublished":"2026-09-17T07:53:24+00:00","dateModified":"2026-09-17T08:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/"},"wordCount":2154,"publisher":{"@id":"https:\/\/docuply.io\/en\/#organization"},"image":{"@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/#primaryimage"},"thumbnailUrl":"https:\/\/docuply.io\/wp-content\/uploads\/2026\/09\/Design-ohne-Titel-1.png","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/","url":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/","name":"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026 | Docuply","isPartOf":{"@id":"https:\/\/docuply.io\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/#primaryimage"},"image":{"@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/#primaryimage"},"thumbnailUrl":"https:\/\/docuply.io\/wp-content\/uploads\/2026\/09\/Design-ohne-Titel-1.png","datePublished":"2026-09-17T07:53:24+00:00","dateModified":"2026-09-17T08:02:15+00:00","description":"For electronic signatures in an FDA-regulated setting, 21 CFR Part 11 requires four things: a validated system, a secure and (...)","breadcrumb":{"@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/#primaryimage","url":"https:\/\/docuply.io\/wp-content\/uploads\/2026\/09\/Design-ohne-Titel-1.png","contentUrl":"https:\/\/docuply.io\/wp-content\/uploads\/2026\/09\/Design-ohne-Titel-1.png","width":2048,"height":2048,"caption":"21 CFR Part 11 Electronic Signatures: Compliance-Guide und Anbietervergleich 2026"},{"@type":"BreadcrumbList","@id":"https:\/\/docuply.io\/en\/21-cfr-part-11-electronic-signatures-guide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/docuply.io\/en\/"},{"@type":"ListItem","position":2,"name":"21 CFR Part 11 Electronic Signatures: Compliance Guide and Vendor Comparison 2026"}]},{"@type":"WebSite","@id":"https:\/\/docuply.io\/en\/#website","url":"https:\/\/docuply.io\/en\/","name":"Docuply","description":"Das elektronische Qualit\u00e4ts\u00admanagement\u00adsystem f\u00fcr Pharma-\u00adKMU und Biotech Start-Ups","publisher":{"@id":"https:\/\/docuply.io\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/docuply.io\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/docuply.io\/en\/#organization","name":"Docuply","url":"https:\/\/docuply.io\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/docuply.io\/en\/#\/schema\/logo\/image\/","url":"https:\/\/docuply.io\/wp-content\/uploads\/2021\/12\/Docuply-Logo-1.0.svg","contentUrl":"https:\/\/docuply.io\/wp-content\/uploads\/2021\/12\/Docuply-Logo-1.0.svg","width":2913,"height":719,"caption":"Docuply"},"image":{"@id":"https:\/\/docuply.io\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/docuplyio","https:\/\/www.linkedin.com\/company\/docuply\/"]},{"@type":"Person","@id":"https:\/\/docuply.io\/en\/#\/schema\/person\/9315e3dd42d30aa7de7672e3f78833f2","name":"klqcsupport","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/da59724f7f91c371ac3ce77a87b08724f7f2ad3567196cf301565601f8e54536?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/da59724f7f91c371ac3ce77a87b08724f7f2ad3567196cf301565601f8e54536?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da59724f7f91c371ac3ce77a87b08724f7f2ad3567196cf301565601f8e54536?s=96&d=mm&r=g","caption":"klqcsupport"},"sameAs":["https:\/\/docuply.io"],"url":"https:\/\/docuply.io\/en\/author\/hostingklqc-de\/"}]}},"_links":{"self":[{"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/pages\/5382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/comments?post=5382"}],"version-history":[{"count":3,"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/pages\/5382\/revisions"}],"predecessor-version":[{"id":5386,"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/pages\/5382\/revisions\/5386"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/media\/5376"}],"wp:attachment":[{"href":"https:\/\/docuply.io\/en\/wp-json\/wp\/v2\/media?parent=5382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}